Prognostic value of liver metastasis in patients with esophageal squamous cell carcinoma treated with nivolumab
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Nivolumab shows real-world efficacy in advanced esophageal cancer, including elderly patients. Liver metastases indicate poorer outcomes, suggesting it as a predictive biomarker for nivolumab treatment.
Area Of Science
- Oncology
- Immunotherapy
- Gastrointestinal Cancer Research
Background
- Nivolumab is approved for unresectable recurrent advanced esophageal cancer.
- Real-world data is needed for diverse patient profiles, including elderly and poor performance status individuals.
- Identifying biomarkers for nivolumab efficacy is crucial.
Purpose Of The Study
- To evaluate the real-world efficacy and safety of nivolumab in advanced esophageal cancer.
- To assess nivolumab's impact on diverse patient populations, including the elderly and those with poor performance status.
- To identify potential biomarkers predicting nivolumab response.
Main Methods
- Retrospective study of 42 esophageal cancer patients treated with nivolumab (second- or later-line).
- Data collected from February 2020 to December 2021 at Kyoto Prefectural University of Medicine.
- Evaluation of outcomes, safety, and clinical characteristics impacting efficacy.
Main Results
- Response rate was 26%, disease control rate was 78%.
- Median progression-free survival was 3.5 months; median overall survival was 19 months.
- Liver metastases significantly worsened progression-free survival (HR 2.37) and overall survival (HR 2.75).
Conclusions
- Nivolumab demonstrates favorable real-world efficacy in advanced esophageal cancer, including elderly patients and those with impaired performance status.
- No serious immune-related adverse events were observed.
- Liver metastasis is a potential predictive biomarker for nivolumab efficacy in esophageal squamous cell carcinoma.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.